The molecular landscape of antibody-mediated kidney transplant rejection: Evidence for NK involvement through CD16a Fc receptors

American Journal of Transplantation

Volumn 15, Issue 5, 2015, Pages 1336-1348

  Venner, J M ^a,b   Hidalgo, L G ^a,b   Famulski, K S ^a,b   Chang, J ^a   Halloran, P F ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

basic (laboratory) research science; biopsy; kidney transplantation nephrology; natural killer (NK) cells NK receptors; rejection: antibody mediated (ABMR); signaling signaling pathways

Indexed keywords

ANGIOPOIETIN; CADHERIN; CD16A FC RECEPTOR; CHEMOKINE RECEPTOR; CXCL11 CHEMOKINE; FC RECEPTOR; GAMMA INTERFERON; GRANULYSIN; PHOSPHOLIPASE A1; SCLEROSTIN; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTIBODY; FCGR3A PROTEIN, HUMAN;

ANTIBODY MEDIATED REJECTION; ARTICLE; EFFECTOR CELL; ENDOTHELIUM INJURY; GRAFT FAILURE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; MACROPHAGE; MICROARRAY ANALYSIS; MONOCYTE; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UMBILICAL VEIN ENDOTHELIAL CELL; ADOLESCENT; ADULT; AGED; ALGORITHM; BIOPSY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHEMISTRY; COHORT ANALYSIS; CYTOLOGY; FACTUAL DATABASE; FEMALE; GRAFT REJECTION; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; METABOLISM; MICROCIRCULATION; MIDDLE AGED; PATHOLOGY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTIBODIES; BIOPSY; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; GRAFT REJECTION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; KILLER CELLS, NATURAL; MACROPHAGES; MALE; MICROCIRCULATION; MIDDLE AGED; RECEPTORS, IGG; YOUNG ADULT;

EID: 84928035596     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13115     Document Type: Article

References (60)

1. Djamali A, Kaufman DB, Ellis TM, Zhong W, Matas A, Samaniego M.; Diagnosis and management of antibody-mediated rejection: Current status and novel approaches. Am J Transplant 2014; 14: 255-271.
2. Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520-2531.
3. Sellares J, De Freitas D, Mengel M, et al. Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and non-adherence. Am J Transplant 2012; 12: 388-399.
4. Halloran PF, Wadgymar A, Ritchie S, Falk J, Solez K, Srinivasa NS.; The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection. Transplant 1990; 49: 85-91.
5. Patel R, Terasaki PI.; Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735-780.
6. Sis B, Campbell PM, Mueller T, et al. Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant 2007; 7: 1743-1752.
7. Feucht HE, Felber E, Gokel MJ, et al. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol 1991; 86: 464-470.
8. Sis B, Jhangri G, Bunnag S, Allanach K, Kaplan B, Halloran PF.; Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009; 9: 2312-2323.
9. Reeve J, Sellares J, Mengel M, et al. Molecular diagnosis of T cell-mediated rejection in human kidney transplant biopsies. Am J Transplant 2013; 13: 645-655.
10. Sellares J, Reeve J, Loupy A, et al. Molecular diagnosis of antibody-mediated rejection in human kidney transplants. Am J Transplant 2013; 13: 971-983.
11. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: Inclusion of C4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014; 14: 272-283.
12. Sarwal M, Chua MS, Kambham N, M, et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003; 349: 125-138.
13. Flechner SM, Kurian SM, Head SR, et al. Kidney transplant rejection and tissue injury by gene profiling of biopsies and peripheral blood lymphocytes. Am J Transplant 2004; 4: 1475-1489.
14. Saint-Mezard P, Berthier CC, Zhang H, et al. Analysis of independent microarray datasets of renal biopsies identifies a robust transcript signature of acute allograft rejection. Transpl Int 2009; 22: 293-302.
15. Kawai T, Sogawa H, Boskovic S, et al. CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates. Am J Transplant 2004; 4: 1391-1398.
16. Smith RN, Kawai T, Boskovic S, et al. Chronic antibody mediated rejection of renal allografts: Pathological, serological and immunologic features in nonhuman primates. Am J Transplant 2006; 6: 1790-1798.
17. Halloran PF, Pereira AB, Chang J, et al. Microarray diagnosis of antibody-mediated rejection in kidney transplant biopsies: An international prospective study (INTERCOM). Am J Transplant 2013; 13: 2865-2874.
18. Halloran PF, Reeve J, Pereira AB, Hidalgo LG, Famulski KF.; Antibody-mediated rejection, T cell-mediated rejection, and the injury-repair response: new insights from the Genome Canada studies of kidney transplant biopsies. Kidney Int 2014; 258-264.
19. Hidalgo LG, Sellares J, Sis B, Mengel M, Chang J, Halloran PF.; Interpreting NK cell transcripts versus T cell transcripts in renal transplant biopsies. Am J Transplant 2012; 12: 1180-1191.
20. Hidalgo LG, Sis B, Sellares J, et al. NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: Evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant 2010; 10: 1812-1822.
21. Shin BH, Ge S, Mirocha J, et al. Regulation of anti-HLA antibody-dependent natural killer cell activation by immunosuppressive agents. Transplant 2014; 97: 294-300.
22. Akiyoshi T, Hirohashi T, Alessandrini A, et al. Role of complement and NK cells in antibody mediated rejection. Hum Immunol 2012; 73: 1226-1232.
23. Hirohashi T, Chase CM, Della PP, et al. A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am J Transplant 2012; 12: 313-321.
24. Hirohashi T, Uehara S, Chase CM, et al. Complement independent antibody-mediated endarteritis and transplant arteriopathy in mice. Am J Transplant 2010; 10: 510-517.
25. Venner JM, Famulski K, Badr D, Hidalgo LG, Chang J, Halloran PF.; Molecular landscape of T cell-mediated rejection in human kidney transplants: Prominence of CTLA4 and PD ligands. Am J Transplant. 2014, in press.
26. Hidalgo LG, Einecke G, Allanach K, Halloran PF.; The transcriptome of human cytotoxic T cells: Similarities and disparities among allostimulated CD4(+) CTL, CD8(+) CTL and NK cells. Am J Transplant 2008; 8: 627-636.
27. Leibson PJ.; Signal transduction during natural killer cell activation: Inside the mind of a killer. Immunity 1997; 6: 655-661.
28. Nimmerjahn F, Ravetch JV.; Fc gamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8: 34-47.
29. Reeve J, Einecke G, Mengel M, et al. Diagnosing rejection in renal transplants: A comparison of molecular- and histopathology-based approaches. Am J Transplant 2009; 9: 1802-1810.
30. Jackson JA, Kim EJ, Begley B, et al. Urinary chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection. Am J Transplant 2011; 11: 2228-2234.
31. Hu H, Aizenstein BD, Puchalski A, Burmania JA, Hamawy MM, Knechtle SJ.; Elevation of CXCR3-binding chemokines in urine indicates acute renal-allograft dysfunction. Am J Transplant 2004; 4: 432-437.
32. Strehlau J, Pavlakis M, Lipman M, et al. Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. Proc Natl Acad Sci USA 1997; 94: 695-700.
33. Kotsch K, Mashreghi MF, Bold G, et al. Enhanced granulysin mRNA expression in urinary sediment in early and delayed acute renal allograft rejection. Transplant 2013; 77: 1866-1875.
34. Li B, Hartono C, Ding R, et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med 2001; 344: 947-954.
35. Latz E, Xiao TS, Stutz A.; Activation and regulation of the inflammasomes. Nat Rev Immunol 2013; 13: 397-411.
36. Famulski KS, Einecke G, Reeve J, et al. Changes in the transcriptome in allograft rejection: IFN-γ induced transcripts in mouse kidney allografts. Am J Transplant 2006; 6: 1342-1354.
37. Famulski KS, Einecke G, Sis B, et al. Defining the canonical form of T-cell-mediated rejection in human kidney transplants. Am J Transplant 2010; 10: 810-820.
38. Hadley TJ, Lu ZH, Wasniowska K, et al. Postcapillary venule endothelial cells in kidney express a multispecific chemokine receptor that is structurally and functionally identical to the erythroid isoform, which is the Duffy blood group antigen. J Clin Invest 1994; 94: 985-991.
39. Totsune K, Takahashi K, MacKenzie HS, et al. Adrenomedullin and its receptor complexes in remnant kidneys of rats with renal mass ablation: Decreased expression of calcitonin receptorlike receptor and receptor-activity modifying protein-3. Peptides 2001; 22: 1933-1937.
40. Bouchon A, Cella M, Grierson HL, Cohen JI, Colonna M.; Cutting edge: Activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family. J Immunol 2001; 167: 5517-5521.
41. Bezman NA, Kim CC, Sun JC, et al. Molecular definition of the identity and activation of natural killer cells. Nat Immunol 2012; 13: 1000-1009.
42. Kveberg L, Bryceson Y, Inngjerdingen M, Rolstad B, Maghazachi AA.; Sphingosine 1 phosphate induces the chemotaxis of human natural killer cells. Role for heterotrimeric G proteins and phosphoinositide 3 kinases. Eur J Immunol 2002; 32: 1856-1864.
43. Le BP, Tabiasco J, Polgar B, et al. C D160: A unique activating NK cell receptor. Immunol Lett 2011; 138: 93-6.
44. Le BP, Barakonyi A, Giustiniani J, et al. Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity. Proc Natl Acad Sci USA 2002; 99: 16963-16968.
45. Graham GJ, Locati M, Mantovani A, Rot A, Thelen M.; The biochemistry and biology of the atypical chemokine receptors. Immunol Lett 2012; 145: 30-38.
46. McLatchie LM, Fraser NJ, Main MJ, et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 1998; 393: 333-339.
47. Berx G, van Roy F.; Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol 2009; 1: 2003129.
48. Samant GV, Schupp MO, Francois M, et al. Sox factors transcriptionally regulate ROBO4 gene expression in developing vasculature in zebrafish. J Biol Chem 2011; 286: 30740-7.
49. Jones CA, London NR, Chen H, et al. Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability. Nat Med 2008; 14: 448-453.
50. Zhuang XD, Cross D, Heath VL, Bicknell R.; Shear stress, tip cells and regulators of endothelial migration. Biochem Soc Trans 2011; 39: 1571-1575.
51. Jeansson M, Gawlik A, Anderson G, et al. Angiopoietin-1 is essential in mouse vasculature during development and in response to injury. J Clin Invest 2011; 121: 2278-2289.
52. Birdsey GM, Dryden NH, Amsellem V, et al. Transcription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin. Blood 2008; 111: 3498-3506.
53. Hayano C, Koi H, Ogawa K, et al. Accumulation of CD16+ cells with secretion of Ksp37 in decidua at the end of pregnancy. Am J Reprod Immunol 2002; 48: 57-62.
54. Maiza H, Leca G, Mansur IG, Schiavon V, Boumsell L, Bensussan A.; A novel 80-Kd cell-surface structure identifies human circulating lymphocytes with natural-killer activity. J Exp Med 1993; 178: 1121-1126.
55. Lanier LL, Ruitenberg JJ, Phillips JH.; Functional and biochemical-analysis of Cd16 antigen on natural-killer cells and granulocytes. J Immunol 1988; 141: 3478-3485.
56. Srivastava S, Pelloso D, Feng HL, et al. Effects of interleukin-18 on natural killer cells: Costimulation of activation through Fc receptors for immunoglobulin. Cancer Immunol Immunother 2013; 62: 1073-1082.
57. Govindan R, Ding L, Griffith M, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 2012; 150: 1121-1134.
58. Prat A, Parker JS, Fan C, et al. Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Ann Oncol 2012; 23: 2866-2873.
59. Seok J, Warren HS, Cuenca AG, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 2013; 110: 3507-3512.
60. Nature medicine editorial. Of men, not mice. Nat Med 2013; 19: 379.